Carbonized aerogel/ZnO-based dispersive solid phase extraction of daclatasvir and sofosbuvir from biological samples prior to liquid chromatography-tandem mass spectrometry.
Biological sample
Daclatasvir
Dispersive solid-phase extraction
High-performance liquid chromatography
Sofosbuvir
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
25
07
2023
revised:
13
10
2023
accepted:
01
11
2023
medline:
6
12
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
ppublish
Résumé
Daclatasvir and sofosbuvir are antiviral medications utilized in the treatment of chronic hepatitis C virus (HCV) infection. Due to their low therapeutic index, careful monitoring is necessary to ensure that the optimal dose is administered. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) is an exceptionally sensitive and specific technique for quantifying these drugs within biological matrices. In this study, we developed a novel dispersive solid-phase extraction method employing a carbonized bio aerogel composite with ZnO for efficient extraction of daclatasvir and sofosbuvir from exhaled breath condensate, urine, and plasma samples. The extracted analytes were subsequently subjected to analysis using HPLC-MS/MS. Optimal parameters including pH adjustment, sorbent quantity variation, and elution solvent selection were fine-tuned to achieve maximum recovery efficiency while ensuring selectivity enhancements. The developed method demonstrated broad linearity ranging between 1.2 and 200 ng/mL along with good precision (relative standard deviations ≤6.2 %) and an acceptable coefficient of determination (r
Identifiants
pubmed: 37995479
pii: S0731-7085(23)00610-6
doi: 10.1016/j.jpba.2023.115841
pii:
doi:
Substances chimiques
Sofosbuvir
WJ6CA3ZU8B
daclatasvir
LI2427F9CI
Zinc Oxide
SOI2LOH54Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115841Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.